Chymotrypsin - instructions for use, dose, side effects, contraindications

Clinical and pharmacological group: & nbsp

Enzymes and antiferments

Included in the formulation

Chymotrypsin®

lyophilizate for injections

SAMSON-MED, LLC Russia

АТХ:

B.06.A.A.04 Chymotrypsin

Pharmacodynamics:

When administered intramuscularly, it exhibits an anti-inflammatory effect due to the cleavage of peptide bonds in the protein molecule, as well as the bonds formed by the residues of aromatic amino acids in the mediators of inflammation.

When topically applied, lyses necrotic tissues, consisting of protein detritus, fibrinous formations, viscous secretions and exudates. Does not interact with viable cells, because they have specific anti- enzymes and non-specific inhibitors of proteolysis.

Pharmacokinetics:

Not described.

Indications:

It is used for the treatment of osteomyelitis, thrombophlebitis, otitis, iritis, iridocyclitis, edema of the periorbital area after surgery, hemorrhage in the anterior chamber of the eye, tracheitis, bronchitis, exudative pleurisy, empyema of the pleura, inflammatory-dystrophic forms of periodontitis. Used as a means for local treatment for burns, purulent wounds and bedsores.

ICD-10

VII.H15-H22.H20.0 Acute and subacute iridocyclitis

VII.H15-H22.H20.1 Chronic iridocyclitis

VII.H15-H22.H21.0 Hyphema

VIII.H65-H75.H66 Purulent and unspecified otitis media

IX.I80-I89.I80 Phlebitis and thrombophlebitis

X.J00-J06.J01 Acute Sinusitis

X.J00-J06.J04 Acute laryngitis and tracheitis

X.J20-J22.J20 Acute bronchitis

X.J30-J39.J32 Chronic Sinusitis

X.J30-J39.J37 Chronic laryngitis and laryngotracheitis

X.J40-J47.J42 Chronic bronchitis, unspecified

X.J85-J86.J86 Pythothrace

X.J90-J94.J90 Pleural effusion, not elsewhere classified

XI.K00-K14.K05 Gingivitis and periodontal disease

XII.L80-L99.L89 Decubital ulcer

XIII.M86-M90.M86 Osteomyelitis

XIX.S00-S09.S05 Injury of the eye and orbit

XIX.T20-T32 Thermal and chemical burns

XIX.T79.T79.3 Post-traumatic wound infection, not elsewhere classified

Contraindications:

Heart failure II-III stage, decompensated forms of pulmonary tuberculosis, liver cirrhosis, infectious hepatitis, pancreatitis, malignant neoplasms, hemorrhagic diathesis, emphysema, respiratory insufficiency, individual intolerance, children under 18 years.

Carefully:

Empyema of the pleura with tuberculosis, hypersensitivity.

Pregnancy and lactation:

Recommendations for FDA - Category C. It is used with caution during pregnancy and lactation in cases where the intended benefit exceeds the risk to the fetus and newborn.

Dosing and Administration:

Intramuscularly 5-10 mg once a day.

Solution: 25-50 mg of chymotrypsin in 10-50 ml of 0.25% solution of procaine. Subconjunctival, in the posterior chamber of the eye. Locally: intrapleural, using a syringe with a long needle under pressure sores or burns; on wounds impose sterile wipes, moistened with a solution, for 8 hours. In otolaryngology, they dig in the ear and inject into the maxillary sinus.

The highest daily dose: 10 mg.

The highest single dose: 10 mg.

Side effects:

The cardiovascular system: tachycardia.

Sense organs: edema and irritation of the conjunctiva.

Dermatological reactions: hyperemia, swelling at the site of intramuscular injection.

Increased body temperature, allergic reactions.

Overdose:

Cases of overdose are not described.

Treatment is symptomatic.

Interaction:

Possible simultaneous use in combination with bronchodilating agents and antibiotics.

It is possible to reduce the absorption of iron with the simultaneous use of anti-anemic drugs.

Special instructions:

Contraindicated to enter the drug in the bleeding cavities and apply to the ulcerated surface of malignant tumors.

Instructions

Chymotrypsin (Chymotrypsinum)